LIDDS AB (publ) announces the appointment of Anders Månsson as CEO
Kurs
+6,79%
Likviditet
0,19 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-20 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | N/A | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2025-05-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-28 | N/A | Årsstämma |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-16 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-02-27 | - | Extra Bolagsstämma 2024 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2023-05-29 | - | Årsstämma |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-13 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2022-06-01 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-22 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-18 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2021-05-18 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-17 | - | Årsstämma |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-28 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-29 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-10-06 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-09 | - | Extra Bolagsstämma 2016 |
| 2016-04-22 | - | Årsstämma |
| 2016-04-22 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-21 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2016-02-10 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-22 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2015-04-21 | - | Årsstämma |
| 2015-04-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-11 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that Anders Månsson will assume the role of Chief Executive Officer for LIDDS, effective September 1st 2022 succeeding Nina Herne.
Anders Månsson has broad experience from leading roles both in the biotech sector and in larger multinational pharmaceutical companies in an international setting over 25 years. His substantial experience in business development from serving as e.g VP & Head of Global Business Development in LEO Pharma will be important for LIDDS in driving the value of current and future collaborations. Anders also has considerable experience from sales & marketing; he has been the Managing Director of a subsidiary in Ferring Pharmaceuticals, and he has headed a major global business unit in LEO Pharma. His experience also includes board-level and executive appointments in biotech companies, and most recently Anders was the CEO of RhoVac.
“I am convinced Anders will be a great leader taking LIDDS to the next level with his experience from licensing and deal-making”, says Jan Törnell, chairman of LIDDS. “Anders has the right leadership capabilities to drive LIDDS and deliver on our business development activities and internal portfolio”.
“I see in LIDDS a company with a proprietary technology platform, that already has a proof of concept with multiple compounds in clinical trials, and that can be applied and licensed over and over again with different known APIs and in different indications where targeted controlled release brings a significant therapeutic advantage”, says Anders Månsson. “I see these opportunities for licensing as virtually endless and, as such, I am thrilled to join the company at this early stage of its growth journey.”
Anders will join LIDDS September 1st.
“We would like to thank Nina for developing LIDDS in an excellent way”, says Jan Törnell “She has successfully led LIDDS through an important transformation period building the organization, creating a strategic vision, and optimizing its processes and portfolio creating a much stronger and solid LIDDS”.
Nina will remain as CEO until Anders is in place to secure a smooth transition.
Nina is leaving LIDDS due to personal reasons.
For additional information, please contact:
Jan Törnell, Chairman LIDDS
Phone:+46 (0)70 676 0008
E-mail: jan.tornell@innoext.se
LIDDS’ Certified Adviser is Redeye AB
Tel: +46 (0)8 121 576 90
E-mail: certifiedadviser@redeye.se
LIDDS in brief:
LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.
This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-07-15 11:00 CEST.